{"id":560833,"date":"2026-07-18T12:35:37","date_gmt":"2026-07-18T10:35:37","guid":{"rendered":"https:\/\/medizinonline.com\/tirzepatida-frente-a-dulaglutida-en-la-diabetes-tipo-2-con-ascvd\/"},"modified":"2026-09-21T11:00:36","modified_gmt":"2026-09-21T09:00:36","slug":"tirzepatida-frente-a-dulaglutida-en-la-diabetes-tipo-2-con-ascvd","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/es\/tirzepatida-frente-a-dulaglutida-en-la-diabetes-tipo-2-con-ascvd\/","title":{"rendered":"Tirzepatida frente a dulaglutida en la diabetes tipo 2 con ASCVD"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Los agonistas del receptor del GLP-1 se han consolidado en los \u00faltimos a\u00f1os como una clase de sustancias con efectos protectores cardiovasculares en la diabetes tipo 2. En el caso del dulaglutido, el estudio REWIND de 2019 demostr\u00f3 que esta sustancia reduce los eventos cardiovasculares graves en comparaci\u00f3n con el placebo, durante un periodo medio de seguimiento de 5,4 a\u00f1os, en el que aproximadamente un tercio de los participantes presentaba una enfermedad cardiovascular establecida y el resto, factores de riesgo cardiovascular. La tirzepatida, un agonista dual de los receptores GLP-1 y GIP, hab\u00eda demostrado en los ensayos de autorizaci\u00f3n (programa SURPASS) un efecto notable sobre la glucemia y el peso corporal. Sin embargo, a\u00fan no se dispon\u00eda de pruebas directas de un beneficio cardiovascular en un estudio de resultados dise\u00f1ado espec\u00edficamente para ello.   <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Ftirzepatida-frente-a-dulaglutida-en-la-diabetes-tipo-2-con-ascvd%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Los agonistas del receptor del GLP-1 se han consolidado en los \u00faltimos a\u00f1os como una clase de sustancias con efectos protectores cardiovasculares en la diabetes tipo 2. En el caso&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/es\/mi-cuenta\/paquetes\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">\u00bfYa eres miembro? <a href=\"https:\/\/medizinonline.com\/es\/conectarse\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Fes%2Ftirzepatida-frente-a-dulaglutida-en-la-diabetes-tipo-2-con-ascvd%2F\">Accede aqu\u00ed<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":560836,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"SURPASS-CVOT","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11552,11324,11352,11475,11408,11478,11288],"tags":[21299,72483],"powerkit_post_featured":[],"class_list":["post-560833","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-es","category-cardiologia","category-endocrinologia-y-diabetologia","category-estudios","category-farmacologia-y-toxicologia","category-formacion-continua","category-medicina-interna-general","tag-dulaglutida","tag-tirzepatida","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-10-16 21:03:09","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"es_ES","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/560833","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/comments?post=560833"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/560833\/revisions"}],"predecessor-version":[{"id":567005,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/posts\/560833\/revisions\/567005"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media\/560836"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/media?parent=560833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/category?post=560833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/tags?post=560833"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/es\/wp-json\/wp\/v2\/powerkit_post_featured?post=560833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}